4

Back to all posts

Equine Amnio Solutions Signs Exclusive Agreement For Distribution Of RenoVō®, A Next-Generation Equine Regenerative Product

By Bree Valensin, DVM

As equine veterinarians, we are often faced with navigating an overwhelming marketplace of biologics, supplements, and adjunctive therapies, each with varying levels of efficacy and practicality. In an industry saturated with countless products promising specialized benefits, finding something that genuinely delivers across multiple disciplines of care is rare.

RenoVō® has become one of those tools in my practice.

While many regenerative products are traditionally associated with soft tissue injury or joint maintenance alone, I have found RenoVō® demonstrates clinical utility far beyond those conventional applications. I have incorporated it into a wide range of therapeutic protocols, including ophthalmic support, nebulization therapy, and intravenous administration aimed at promoting overall systemic wellness and recovery. Having a single therapeutic option that is both accessible and adaptable across so many areas of care has proven truly invaluable.

What distinguishes RenoVō® most is its ability to integrate the most beneficial qualities of numerous regenerative and supportive therapies into one refined product. It simplifies that landscape without compromising clinical performance. Throughout my experience utilizing it in practice, I have observed meaningful improvements not only in recovery and athletic longevity, but also in the overall vitality and long-term health of my equine patients.

Perhaps most significantly, RenoVō® has proven especially valuable in the management of aging horses and those affected by metabolic conditions where corticosteroid use may be limited or contraindicated altogether. These patients often require a far more nuanced and conscientious treatment strategy. Having a therapy that supports healing, comfort, and physiologic resilience without heavy reliance on steroids has been extraordinarily beneficial. Witnessing these horses maintain soundness, comfort, and quality of life well into their later years has been deeply rewarding.

To me, RenoVō® represents far more than a therapeutic product. It is an investment in the longevity, wellness, and sustained performance of the horses entrusted to our care.

About the Author

Bree Valensin, DVM is an equine veterinarian based in Weatherford, Texas and founder of Valensin Equine. She earned her veterinary degree from Midwestern University in Phoenix and brings extensive experience working with performance horses. She has incorporated RenoVō® into her therapeutic protocols at her discretion across a wide range of equine cases.

RenoVō® is a liquid, acellular, equine amniotic tissue allograft comprised of amnion and amniotic fluid, intended to supplement and protect tissues. Clinical decisions regarding its use are made at the discretion of the attending veterinarian.

ARGYLE, TEXAS, March 25, 2021 — Equine Amnio Solutions, LLC (EAS), a distributor of advanced, next-generation equine regenerative products, announced today that Covetrus, a global leader in animal health technology and services, will be the exclusive distributor of the RenoVō® equine allograft throughout the United States.

RenoVō® is an acellular, cryopreserved liquid allograft derived from equine amniotic tissues intended for equine use. Amniotic birth tissues are rich sources of bioactive factors involved in tissue regeneration with reported anti-inflammatory, anti-bacterial and anti-fibrotic properties.

RenoVō® is uniquely processed through a proprietary process to optimize protein retention and stability. The product is supplied in volumes of 1.5 cc, 3.0 cc and 5.0 cc and is maintained frozen before use to preserve beneficial proteins which may not survive desiccation procedures common to industry. Compelling clinical evidence has established the product as a safe and efficacious option for the equine practitioner and RenoVō® continues to enjoy rapid adoption among veterinarians and owners as an alternative to autologous and other therapies.

EAS works closely with its product manufacturer, Equus Innovations (Phoenix, Arizona). Grant D. Senner, MD, DABRM and Equus Innovations’ Chief Executive Officer stated, “We are extremely excited to partner with Covetrus to expand the distribution and clinical use of RenoVō®. Our mission has always been to provide innovative products to maximize the health and performance of horses across all breeds and athletic disciplines. Covetrus is the ideal partner to help us establish RenoVō® as a new standard of care for the equine practitioner.”

About Equine Amnio Solutions

Equine Amnio Solutions, LLC (EAS) is the market leader in the distribution of next-generation regenerative veterinary products, including RenoVō®. EAS works closely with its product manufacturer, Equus Innovations (Phoenix, Arizona). Our mission is to provide innovative products to maximize the health and performance of horses across all breeds and athletic disciplines.

RenoVō® is a Registered Trademark of Equine Amnio Solutions, LLC.

You may want to read these articles